<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of antiplatelet agents in patients undergoing endoscopic procedures</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of antiplatelet agents in patients undergoing endoscopic procedures</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of antiplatelet agents in patients undergoing endoscopic procedures</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick S Kamath, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Management of antiplatelet agents in patients undergoing endoscopic procedures is challenging because interrupting antithrombotic therapy transiently increases the risk of thromboembolism. At the same time, some endoscopic interventions may have bleeding risks that are increased by the antiplatelet agent given for thromboembolism prevention. Limited data are available to guide the management of patients on antiplatelet agents in these settings. </p><p>This topic will review the periprocedural management of patients taking antiplatelet agents for the prevention of thromboembolism. The management of patients taking anticoagulants, as well as patients with disorders of hemostasis (eg, von Willebrand disease, hemophilia) are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a>.)</p><p>The therapeutic effect of antiplatelet agents is impaired platelet function, including preventing platelet activation and inhibiting platelet aggregation. The mechanism of action of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in low doses is inhibition of cyclooxygenase and platelet generation of thromboxane A2, resulting in an antithrombotic effect. <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a>, <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>, <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>, and <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> inhibit platelet function by binding to the P2Y<sub>12</sub> component of the adenosine diphosphate receptors which prevents activation of the GPIIb/IIIa receptor complex, thus reducing platelet aggregation. Aspirin, clopidogrel, ticlopidine, or prasugrel irreversibly inhibit platelet function for 7 to 10 days, corresponding to the average lifespan of platelets. The mechanism of action of antiplatelet agents is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Platelet receptors and their agonists'</a>.)</p><p>The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines regarding the management of patients taking antiplatelet agents based upon the available evidence and consensus opinion [<a href="#rid1">1</a>]. The recommendations in this topic are consistent with the ASGE guidelines. This topic is also addressed in guidelines from the American College of Gastroenterology, the American College of Chest Physicians, the British Society of Gastroenterology/European Society of Gastrointestinal Endoscopy, the American College of Cardiology/American Heart Association, and the American College of Surgeons, which make similar (although not identical) recommendations [<a href="#rid2">2-6</a>].</p><p class="headingAnchor" id="H144713279"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3945793887"><span class="h2">Factors that guide decision-making</span><span class="headingEndMark"> — </span>The management of antiplatelet agents for patients undergoing endoscopy takes into account the patient’s risk of thromboembolic complications in the absence of antiplatelet therapy, the procedure-related bleeding risk, and the specific features of the antiplatelet agent [<a href="#rid7">7,8</a>].</p><p>Much of our approach is based on expert opinion; thrombotic and bleeding risks may vary depending on individual circumstances, and data from randomized trials or well-designed observational studies are unlikely to be available to guide clinical practice in all settings. Thus, the approach is not based on high-quality evidence and is intended only as clinical guidance in decisions about periprocedural management of antiplatelet agents.</p><p class="headingAnchor" id="H1843585905"><span class="h2">Assessing individual patient risk</span></p><p class="headingAnchor" id="H4"><span class="h3">Estimating thromboembolic risk</span><span class="headingEndMark"> — </span>The probability of a thromboembolic complication following discontinuation of antiplatelet agents depends on the condition for which the medication was prescribed. A higher thromboembolic risk increases the importance of either minimizing or avoiding a time interval without therapy. We consult with the clinician who is managing the patient’s antiplatelet therapy to estimate the thromboembolic risk. (See <a class="local">'Specialty consultation'</a> below and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Specialty consultation'</a>.)</p><p>Antiplatelet agents are used in patients who have a history of or who are at risk for cerebrovascular events, acute coronary syndromes, percutaneous coronary or vascular interventions with stenting, or peripheral arterial disease. Patients are at high risk for complications such as stent thrombosis if antiplatelet therapy is discontinued prematurely  (<a class="graphic graphic_table graphicRef121390" href="/z/d/graphic/121390.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">"Noncardiac surgery after percutaneous coronary intervention", section on 'Statement of the problem'</a> and  <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">"Noncardiac surgery after percutaneous coronary intervention", section on 'Nonemergency noncardiac surgery'</a>.) </p><p>When possible, interventional endoscopic procedures should be delayed for a minimum of one month but ideally for at least six months from the time of the index cardiovascular event. For patients who are within six months of starting dual antiplatelet therapy (DAPT) but who require an endoscopic procedure, management depends on the procedure-related bleeding risk  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>) (see <a class="local">'P2Y12 receptor blockers'</a> below and <a class="local">'Dual antiplatelet therapy'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>If bleeding risk from an endoscopic procedure is low, DAPT is continued periprocedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If bleeding risk from an endoscopic procedure is high, P2Y<sub>12</sub> inhibitor therapy is discontinued for the minimum duration that is possible, while <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is continued. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If bleeding risk from an endoscopic procedure is very high (eg, endoscopic mucosal resection [EMR] of a polyp ≥2 cm), <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and P2Y<sub>12</sub> inhibitor therapy are interrupted. However, most elective procedures can be delayed until the minimum duration of DAPT has been completed.</p><p></p><p>Indirect data on whether discontinuing antiplatelet therapy before surgery impacts mortality, bleeding requiring transfusions, or ischemic events have been uncertain [<a href="#rid10">10</a>]. Analysis of administrative databases suggests that the risk of major adverse cardiac and cerebrovascular events related to interruption of antiplatelet agents was linked to the time interval between coronary stent placement and interruption of antithrombotic therapy. The risk of adverse events was high during the first month but continued to be increased for three to six months after coronary stent placement [<a href="#rid11">11</a>]. In contrast, in the <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">Tranexamic Acid</a> for Coronary Artery Surgery (ATACAS) trial addressing antiplatelet interruption for coronary artery bypass graft surgery, there were no significant differences in the risk of a primary outcome (ie, nonfatal myocardial infarction, stroke, or pulmonary embolism) or in rates of bleeding for patients on aspirin compared with placebo [<a href="#rid12">12</a>]. In addition, outcomes at one year were not significantly different between the groups [<a href="#rid13">13</a>]. Thus, even with high-risk interventions, the likelihood of added thromboembolic protection from perioperative ASA was not evident, and discontinuation of antiplatelet agents for noncardiac interventions with high bleeding risk may be safe. However, in a meta-analysis of 46 studies including &gt;30,000 patients who had noncardiac surgery (endoscopic procedures were excluded), antiplatelet agents were associated with minimal increased bleeding risk but no increase in thromboembolic complications [<a href="#rid14">14</a>]. </p><p>Risk factors for cardiac stent thrombosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a>.)</p><p>Indications for antiplatelet agents and management of the underlying diseases are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary prevention of cardioembolic events in patients with a history of stroke (see  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary prevention of cardioembolic events in patients with a history of myocardial infarction (see  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Antiplatelet therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of stent thrombosis in patients who have undergone coronary stenting (see  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term management for patients with peripheral arterial disease (see  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease"</a>)</p><p></p><p class="headingAnchor" id="H3107918324"><span class="h3">Estimating procedure-related bleeding risk</span><span class="headingEndMark"> — </span>The risk of bleeding depends on the endoscopic procedure and the need for (and type of) therapeutic intervention. (See  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Estimating procedure-related bleeding risk'</a>.).</p><p>Common low risk procedures (bleeding risk &lt;1 percent) include  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Upper gastrointestinal endoscopy (esophagogastroduodenoscopy [EGD]) including mucosal biopsy</p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy including mucosal biopsy</p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic retrograde cholangiopancreatography (ERCP) without sphincterotomy</p><p class="bulletIndent1"><span class="glyph">●</span>ERCP with biliary stent placement but without sphincterotomy</p><p></p><p>Common high-risk procedures (bleeding risk ≥1 percent) include:</p><p class="bulletIndent1"><span class="glyph">●</span>EGD with esophageal variceal ligation</p><p class="bulletIndent1"><span class="glyph">●</span>EGD with esophageal dilation </p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous endoscopic gastrostomy tube placement</p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy with resection of polyp ≥1 cm</p><p class="bulletIndent1"><span class="glyph">●</span>ERCP with biliary or pancreatic sphincterotomy</p><p></p><p>The approach to managing antiplatelet agents depends on whether the procedure is low or high risk for bleeding. For some procedures (ie, screening colonoscopy), the preprocedure estimate of bleeding risk is uncertain because it is unknown whether a high-risk intervention (ie, removal of polyp ≥1 cm) will be necessary. For patients undergoing a procedure with uncertain risk, management options depend on the patient's risk of thrombosis and the specific antiplatelet agent. (See <a class="local">'Elective procedures'</a> below.)</p><p>Measures to prevent bleeding after colonoscopy (eg, polypectomy techniques, use of hemoclips) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2671.html" rel="external">"Management and prevention of bleeding after colonoscopy with polypectomy"</a>.)<strong> </strong></p><p class="headingAnchor" id="H3920340060"><span class="h2">Specialty consultation</span><span class="headingEndMark"> — </span>We consult with the clinician who is managing the patient's long-term anticoagulation (eg, cardiologist, neurologist, vascular specialist) to estimate the patient's thrombotic risk and to determine if antiplatelet therapy can be safely interrupted.</p><p class="headingAnchor" id="H2738728733"><span class="h1">URGENT PROCEDURES FOR GI BLEEDING</span><span class="headingEndMark"> — </span>For patients with gastrointestinal (GI) bleeding, the risk of discontinuing antiplatelet therapy should be weighed against the risk of continued bleeding without interrupting therapy. The approach is individualized based on the severity and source of GI bleeding, the risk of rebleeding after achieving hemostasis, the specific antiplatelet agent(s), and the patient's thrombotic risk as determined by the clinician managing the antiplatelet therapy [<a href="#rid1">1</a>]. (See <a class="local">'Specialty consultation'</a> above and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Specialty consultation'</a>.)</p><p class="headingAnchor" id="H1759946055"><span class="h2">Patients with life-threatening bleeding</span><span class="headingEndMark"> — </span>For patients with life-threatening GI bleeding, we discontinue all antiplatelet agents. Management may also include platelet transfusion, if rapid correction of platelet dysfunction is necessary [<a href="#rid15">15,16</a>]. Indications for and risks of platelet transfusion in the setting of active bleeding are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks"</a>.) </p><p>The duration of platelet dysfunction varies depending on the specific antiplatelet agent. For example, platelet aggregation gradually returns to baseline in approximately three to nine days after discontinuing a P2Y<sub>12</sub> receptor blocker. In contrast, GPIIb/IIIa inhibitors have shorter durations of activity (eg, <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a> or <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a>: four to eight hours). (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Glycoprotein IIb/IIIa inhibitors'</a>.)</p><p class="headingAnchor" id="H3930529612"><span class="h2">Patients with non-severe bleeding</span><span class="headingEndMark"> — </span>The approach to patients with nonsevere GI bleeding prior to endoscopic evaluation primarily depends on the patient's thrombotic risk determined in consultation with the clinician who is managing the patient's antithrombotic therapy  (<a class="graphic graphic_table graphicRef121390" href="/z/d/graphic/121390.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low thrombotic risk</strong> – For patients with low thrombotic risk, antiplatelet therapy is generally interrupted, and the timing for restarting antiplatelet agents is determined after endoscopic evaluation and achieving hemostasis. (See <a class="local">'Restarting antiplatelet therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High thrombotic risk</strong> – For patients with high thrombotic risk, antiplatelet therapy is generally continued prior to endoscopic evaluation. Gastrointestinal bleeding in a high-risk patient poses unique therapeutic challenges because interrupting antiplatelet therapy increases the risk of complications (eg, myocardial ischemic events, stent thrombosis) but it is sometimes necessary to achieve endoscopic hemostasis [<a href="#rid17">17,18</a>]. The management of antiplatelet therapy in this setting is individualized with input from a multidisciplinary team, and this is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p></p><p class="headingAnchor" id="H39098677"><span class="h2">Restarting antiplatelet therapy</span><span class="headingEndMark"> — </span>The timing for restarting antiplatelet therapy depends on whether the risk of rebleeding is low or high based on the bleeding source, and this risk assessment is done by the endoscopist. An example of a lesion with a low rebleeding risk is a clean-based duodenal ulcer, while a duodenal ulcer with a visible vessel initially has a higher risk of rebleeding following endoscopic treatment  (<a class="graphic graphic_table graphicRef78607" href="/z/d/graphic/78607.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">"Overview of the treatment of bleeding peptic ulcers", section on 'Stigmata of recent hemorrhage'</a>.) </p><p class="headingAnchor" id="H185417169"><span class="h3">Patients with low rebleeding risk</span><span class="headingEndMark"> — </span>Patients are regarded as having low rebleeding risk if either of the following conditions is noted at endoscopy:</p><p class="bulletIndent1"><span class="glyph">●</span>A lesion at low risk for rebleeding (ie, duodenal ulcer with a clean base), provided that hemostasis has been achieved </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No bleeding source identified and no active bleeding seen</p><p></p><p>The approach to and timing for restarting antiplatelet therapy after achieving hemostasis in patients with low rebleeding risk depends on the specific agent:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients on P2Y<sub>12</sub> receptor blockers – We wait one to three days (depending on the agent) following hemostasis to restart P2Y<sub>12</sub> receptor blockers (see <a class="local">'P2Y12 receptor blockers'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a>: one day after procedure</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a>: two to three days after procedure</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a>: two to three days after procedure </p><p></p><p class="bulletIndent1">The reinitiation of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is not delayed beyond one day because of its slower onset of action (24 hours) compared with <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> that reach their peak antiplatelet effect more quickly (two to four hours).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> – We wait one day following endoscopic hemostasis to restart aspirin.</p><p></p><p>Data are limited regarding the timing for and benefit of restarting antiplatelet agents; however, several society guidelines favor restarting antiplatelet therapy after hemostasis is achieved [<a href="#rid1">1,19,20</a>]. In addition, resuming <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for secondary prevention reduces the mortality risk [<a href="#rid19">19</a>]. In a trial of 156 patients with a history of either cardiovascular or cerebrovascular disease and with bleeding from peptic ulcer disease, restarting low-dose aspirin (80 mg daily) after achieving endoscopic hemostasis reduced the mortality risk compared with placebo (hazard ratio [HR] 0.2, 95% CI 0.05-0.70). However, there was a trend toward an increase in rebleeding risk in the aspirin group compared with placebo (HR 1.9, 95% CI 0.6-6.0). </p><p class="headingAnchor" id="H3748212770"><span class="h3">Patients with high rebleeding risk</span><span class="headingEndMark"> — </span>For most patients with lesions at high risk of rebleeding (ie, duodenal ulcer with active bleeding)  (<a class="graphic graphic_table graphicRef78607" href="/z/d/graphic/78607.html" rel="external">table 3</a>), we delay restarting antiplatelet therapy (if possible, depending on the patient's thrombotic risk) until the rebleeding risk is lower. (See <a class="local">'Patients with low rebleeding risk'</a> above and  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p>The duration of the delay is based on several factors, including the source and location of bleeding, the endoscopic method used to achieve hemostasis, the hemodynamic status of the patient, the patient's underlying thrombotic risk, and the potential consequences of rebleeding (eg, need for surgical intervention).</p><p>Risk factors associated with rebleeding and the natural history of specific gastrointestinal lesions are discussed in various UpToDate topics on gastrointestinal bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">"Overview of the treatment of bleeding peptic ulcers", section on 'Risk factors for persistent or recurrent bleeding'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'Risk stratification'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Natural history and prognosis with treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2641.html" rel="external">"Colonic diverticular bleeding", section on 'Risk of rebleeding and complications'</a>.)</p><p></p><p class="headingAnchor" id="H1151413442"><span class="h1">NON-ELECTIVE PROCEDURES FOR NONBLEEDING INDICATIONS</span><span class="headingEndMark"> — </span>When non-elective endoscopic procedures are required for patients on antiplatelet agents who are not actively bleeding (ie, patients with acute cholangitis from biliary obstruction), management options include a temporary, low-risk endoscopic intervention (ie, biliary stent without sphincterotomy) in order to delay the need for a procedure that carries a higher risk of bleeding  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/636.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding", section on 'Preventive strategies'</a>.)</p><p>However, some patients (ie, those with obstructive jaundice from pancreatic cancer) may require a high-risk endoscopic intervention (ie, biliary sphincterotomy) prior to biliary stent placement or may require endoscopic ultrasound with biopsy for diagnostic purposes. (See  <a class="medical medical_review" href="/z/d/html/13925.html" rel="external">"Endoscopic stenting for malignant biliary obstruction"</a> and  <a class="medical medical_review" href="/z/d/html/2501.html" rel="external">"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Endoscopic ultrasound-guided biopsy'</a>.)</p><p>The management of patients on antiplatelet therapy who require a non-elective, high-risk endoscopic intervention for conditions other than gastrointestinal bleeding is similar to the management of patients who need urgent endoscopic therapy for gastrointestinal bleeding. (See <a class="local">'Urgent procedures for GI bleeding'</a> above.)</p><p>If a high-risk endoscopic intervention cannot be delayed and rapid reversal of the antiplatelet effect is required, platelet transfusion may be given if the risk of procedure-related bleeding outweighs the risk of thrombotic events. (See <a class="local">'Assessing individual patient risk'</a> above.)</p><p class="headingAnchor" id="H2286216691"><span class="h1">ELECTIVE PROCEDURES</span></p><p class="headingAnchor" id="H2096815245"><span class="h2">Low risk procedures</span><span class="headingEndMark"> — </span>No change in antiplatelet therapy is required prior to elective procedures with a low bleeding risk  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>) (eg, upper gastrointestinal endoscopy [esophagogastroduodenoscopy] or colonoscopy, including mucosal biopsy) [<a href="#rid1">1</a>]. However, for most patients scheduled for screening colonoscopy, the bleeding risk is uncertain because it is unknown whether or not removal of a polyp ≥1 cm will be required. Our approach to management in this setting is similar to that for high-risk procedures because an elective colonoscopy can be delayed until the patient's thrombotic risk is lower(See <a class="local">'High or uncertain risk procedures'</a> below.)</p><p class="headingAnchor" id="H1775202615"><span class="h2">High or uncertain risk procedures</span></p><p class="headingAnchor" id="H2162043582"><span class="h3">Timing of elective procedure</span><span class="headingEndMark"> — </span>Whether an elective, high (or uncertain) risk procedure (eg, screening colonoscopy where polypectomy may be required) is performed or is delayed is guided by the patient's thrombotic risk (see <a class="local">'Estimating thromboembolic risk'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients at low thrombotic risk, an elective procedure can be performed after most antiplatelet agents (excluding <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) are temporarily discontinued. The approach to interruption and resumption of antiplatelet agents depends on the agent used. (See <a class="local">'Adjusting antiplatelet agents'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients at transiently high thrombotic risk, we delay elective procedures until the patient's thrombotic risk is lower, as determined by the indication for antiplatelet therapy and in consultation with the clinician who is managing the patient's anticoagulation (eg, cardiologist, neurologist). (See  <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">"Noncardiac surgery after percutaneous coronary intervention"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p></p><p class="bulletIndent1">For example, our practice of delaying elective high-risk procedures for patients with cardiac stenting within the previous six months is based upon indirect data showing higher rates of stent thrombosis and other cardiovascular complications with premature cessation of dual antiplatelet therapy (DAPT) in the setting of noncardiac surgery, and these issues are discussed separately [<a href="#rid21">21-28</a>]. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p></p><p class="headingAnchor" id="H2601364077"><span class="h3">Adjusting antiplatelet agents</span></p><p class="headingAnchor" id="H880589011"><span class="h4">P2Y12 receptor blockers</span><span class="headingEndMark"> — </span>For high- or uncertain-risk endoscopic procedures in low-risk patients on P2Y<sub>12</sub> receptor blockers (ie, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>), our approach is the following [<a href="#rid7">7,8,29</a>] (see  <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">"Noncardiac surgery after percutaneous coronary intervention", section on 'Nonemergency noncardiac surgery'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue the drug prior to the procedure (time interval depends on the specific agent):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a>: five to seven days </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a>: five to seven days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a>: two to three days (reversible P2Y<sub>12</sub> inhibitor)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">Ticlopidine</a>: 10 to 14 days </p><p></p><p class="bulletIndent1">These time frames represent the minimum duration of interrupting the antiplatelet agent that results in normal platelet aggregation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform endoscopic procedure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restart P2Y<sub>12</sub> receptor blocker for most patients, provided that hemostasis has been achieved, as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a>: one day after procedure</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a>: two to three days after procedure</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a>: two to three days after procedure</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">Ticlopidine</a>: one day after procedure</p><p></p><p class="bulletIndent1">The decision to restart antiplatelet therapy is contingent upon achieving hemostasis as determined by the endoscopist. If the procedure-related bleeding risk is determined to be very high (ie, endoscopic mucosal resection [EMR] of a polyp ≥2 cm), the P2Y<sub>12</sub> receptor blocker may be restarted after four to seven days.</p><p></p><p>We restart <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> one day after the procedure with a one-time dose that is equal to twice the patient's usual maintenance dose (maximum 150 mg) and on day 2 resume the patient's usual maintenance dose. For example, if the patient's maintenance dose of clopidogrel is 75 mg daily, a one-time loading dose of 150 mg is given one day after the procedure, and beginning on day 2, the patient resumes 75 mg once daily.</p><p>Reinitiation of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is not delayed beyond one day because of its slower onset of action (ie, 24 hours) compared with other agents (<a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>) that reach their peak antiplatelet effect more quickly (two to four hours). </p><p>P2Y<sub>12</sub> receptor blockers are held prior to high-risk endoscopic procedures to lower the risk of procedure-related bleeding. For example, some studies suggest that the use of P2Y<sub>12</sub> platelet receptor blockers may increase the risk of postpolypectomy bleeding [<a href="#rid30">30-32</a>]. The effect of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> on postpolypectomy bleeding was examined in a meta-analysis of five observational studies with 6743 patients [<a href="#rid33">33</a>]. At the time of colonoscopy, 574 patients (9 percent) were taking clopidogrel, with or without <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. The rate of postpolypectomy bleeding was higher in patients receiving clopidogrel compared with those who were not (6 versus 2 percent; risk ratio 2.5, 95% CI 1.7-3.8). (See  <a class="medical medical_review" href="/z/d/html/2671.html" rel="external">"Management and prevention of bleeding after colonoscopy with polypectomy"</a>.)</p><p class="headingAnchor" id="H6"><span class="h4">Aspirin</span><span class="headingEndMark"> — </span>We do not routinely stop <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> prior to high-risk endoscopic procedures; however, we typically do not give aspirin immediately following the procedure. Aspirin is resumed one day after the procedure, provided that hemostasis is achieved. Our approach is consistent with society guidelines [<a href="#rid1">1</a>]; however, for patients on aspirin for primary prevention, we delay restarting aspirin for 7 to 10 days for patients who undergo EMR of a colon polyp ≥2 cm or other high risk, advanced procedures (ie, endoscopic submucosal dissection [ESD]). </p><p>In addition, some advanced endoscopists and UpToDate contributors hold <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for five to seven days prior to selected high-risk procedures (eg, EMR, ESD) if aspirin is being given for primary prevention. However, we do not interrupt aspirin therapy if it is being given for secondary prevention. (See  <a class="medical medical_review" href="/z/d/html/2671.html" rel="external">"Management and prevention of bleeding after colonoscopy with polypectomy", section on 'Measures to prevent bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/2673.html" rel="external">"Overview of endoscopic resection of gastrointestinal tumors"</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> use in patients undergoing endoscopic sphincterotomy and colon polypectomy (polyps &lt;2 cm) does not increase bleeding risk [<a href="#rid34">34-39</a>]. (See  <a class="medical medical_review" href="/z/d/html/636.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding", section on 'Antiplatelet agents (excluding aspirin)'</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> use in patients undergoing selected advanced procedures (eg, EMR, ESD) results in a higher risk of bleeding [<a href="#rid40">40-44</a>]; however, indirect evidence shows that the risk of thrombosis increases in patients on aspirin for secondary prevention when it is held [<a href="#rid45">45-47</a>]. In a trial of 220 patients on aspirin for secondary prevention who were undergoing noncardiac surgery, patients on continuous aspirin therapy had lower rates of postoperative cardiac events compared with patients in whom aspirin was held (2 versus 9 percent) [<a href="#rid45">45</a>]. There were no differences in bleeding complications between the two groups. (See  <a class="medical medical_review" href="/z/d/html/2673.html" rel="external">"Overview of endoscopic resection of gastrointestinal tumors", section on 'Endoscopic submucosal dissection'</a>.)</p><p class="headingAnchor" id="H1997373851"><span class="h4">Dual antiplatelet therapy</span><span class="headingEndMark"> — </span>P2Y<sub>12</sub> receptor blockers (eg, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a>, or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>) are used in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for the treatment of acute coronary syndromes and cardiovascular and cerebrovascular disease, and this regimen is referred to as DAPT. For high- or uncertain-risk endoscopic procedures in patients on long-term dual antiplatelet therapy (ie, clopidogrel plus aspirin) who have completed the minimum duration of uninterrupted dual therapy, we discontinue the P2Y<sub>12</sub> receptor blocker between two and seven days (depending on the specific agent) prior to the procedure while aspirin is continued without interruption [<a href="#rid1">1,2</a>]. We perform the procedure and then restart the P2Y<sub>12</sub> receptor blocker in one to three days (depending on the specific agent), provided that hemostasis has been achieved. (See <a class="local">'P2Y12 receptor blockers'</a> above and <a class="local">'Estimating thromboembolic risk'</a> above.)</p><p>The practice of temporarily discontinuing the P2Y<sub>12</sub> receptor blocker while continuing <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for patients who have completed initial therapy with DAPT for cardiac stents is probably safe, and several studies have evaluated thrombotic risk in this setting [<a href="#rid48">48-50</a>]. In general, the risk of a thromboembolic complication is higher when DAPT is interrupted earlier (ie, within the first month) compared with later (between one and 12 months), and these issues are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Patients needing temporary discontinuation'</a> and  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H3440860111"><span class="h4">Dipyridamole</span><span class="headingEndMark"> — </span>Periprocedural management of <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> depends on whether it is being given alone or in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid7">7</a>] (see  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke", section on 'Aspirin plus dipyridamole'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients on <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> alone, we perform high-risk endoscopic interventions without interrupting therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>, we discontinue aspirin-extended-release dipyridamole two to three days before the procedure and continue <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone. We restart aspirin-extended-release dipyridamole one day after the procedure if hemostasis was achieved. </p><p></p><p>Limited data suggest that <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> may increase the risk of bleeding after high-risk endoscopic interventions [<a href="#rid51">51</a>]. <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">Dipyridamole</a> alone probably does not increase the bleeding risk; however, no studies in this setting are available.</p><p>Some advanced endoscopists hold all dipyridamole-based therapies prior to selected high-risk procedures (ie, endoscopic mucosal resection). If it is determined that the procedure-related bleeding risk is greater than the potential benefit of continuing <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> during the periprocedural period (through consultation with the endoscopist and the clinician managing therapy), medication adjustments are as follows (see  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Other antiplatelet agents'</a> and  <a class="medical medical_review" href="/z/d/html/2577.html" rel="external">"Endoscopic removal of large colon polyps", section on 'Endoscopic mucosal resection techniques'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">Dipyridamole</a> alone: Discontinue two to three days prior to procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">Aspirin-extended-release dipyridamole</a>: Discontinue two to three days prior to procedure, but <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> monotherapy is given while <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> is being held.</p><p></p><p><a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">Dipyridamole</a> reversibly inhibits platelet aggregation, has an elimination half-life of 12 hours, and is typically given to patients with history of stroke or transient ischemia attack. (See  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke", section on 'Aspirin plus dipyridamole'</a>.) </p><p class="headingAnchor" id="H1090202099"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120175.html" rel="external">"Society guideline links: Endoscopy preparation, sedation, and special considerations"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The probability of a thromboembolic complication following discontinuation of antiplatelet agents depends upon the condition for which the medication was prescribed  (<a class="graphic graphic_table graphicRef121390" href="/z/d/graphic/121390.html" rel="external">table 1</a>). (See <a class="local">'Estimating thromboembolic risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of bleeding from endoscopic procedures can be classified as high or low. In general, diagnostic procedures (with or without biopsy) are low risk, whereas therapeutic procedures are high risk  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>). (See <a class="local">'Estimating procedure-related bleeding risk'</a> above and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Estimating procedure-related bleeding risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We consult with the clinician managing the patient’s antiplatelet therapy (eg, cardiologist, neurologist, vascular specialist) prior to interrupting antiplatelet agents. (See <a class="local">'Specialty consultation'</a> above and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Specialty consultation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on antiplatelet therapy with gastrointestinal (GI) bleeding, the risk of stopping or reversing the effects of antiplatelet therapy should be weighed against the risk of continued bleeding in the setting of platelet dysfunction. The approach is individualized based on the severity of GI bleeding, the risk of rebleeding after achieving hemostasis, the specific antiplatelet agent(s), and the patient's thrombotic risk as determined by the clinician managing the antiplatelet therapy. (See <a class="local">'Urgent procedures for GI bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing elective procedures with low bleeding risk  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>), no interruption of antiplatelet therapy is required. (See <a class="local">'Low risk procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing elective procedures with a high or uncertain bleeding risk  (<a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">table 2</a>), we take the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients at low thrombotic risk on P2Y<sub>12</sub> receptor blockers, we suggest discontinuing the P2Y<sub>12</sub> receptor blockers prior to elective high-or uncertain-risk procedures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The duration for holding a P2Y<sub>12</sub> receptor blocker prior to the procedure is as follows (see <a class="local">'P2Y12 receptor blockers'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a>: five to seven days </p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a>: five to seven days</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a>: two to three days</p><p></p><p class="bulletIndent2">We restart P2Y<sub>12 </sub>receptor blockers for most patients in one to three days (depending on the specific agent) after the endoscopic intervention, provided that hemostasis has been achieved as determined by the endoscopist.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients at low thrombotic risk taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, we suggest continuing aspirin prior to elective high- or uncertain-risk endoscopic procedures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For most patients, we resume aspirin on the day following the procedure, provided that hemostasis was achieved following endoscopic intervention. However, for patients who undergo selected high-risk procedures (eg, endoscopic mucosal resection or endoscopic submucosal dissection) and who are on aspirin for primary prevention, we delay restarting aspirin for 7 to 10 days. (See <a class="local">'Aspirin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on long-term dual antiplatelet therapy (ie, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) who have completed the minimum duration of uninterrupted dual therapy, we discontinue the P2Y<sub>12</sub> receptor blocker for two to seven days (depending on the agent) prior to a high- or uncertain-risk endoscopic procedure, while aspirin is continued without interruption. The P2Y<sub>12</sub> platelet receptor blocker is restarted in one to three days (depending on the agent) after the procedure, provided that hemostasis has been achieved following endoscopic intervention. (See <a class="local">'Dual antiplatelet therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with transiently high thrombotic risk, we delay elective endoscopic procedures with a high or uncertain bleeding risk until the patient's thrombotic risk is lower. (See <a class="local">'Timing of elective procedure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management of patients on anticoagulants or patients with disorders of hemostasis (eg, thrombocytopenia, renal failure) are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3.</a></li><li><a class="nounderline abstract_t">Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.</a></li><li><a class="nounderline abstract_t">Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2016; 133:1135.</a></li><li><a class="nounderline abstract_t">Hornor MA, Duane TM, Ehlers AP, et al. American College of Surgeons' Guidelines for the Perioperative Management of Antithrombotic Medication. J Am Coll Surg 2018; 227:521.</a></li><li><a class="nounderline abstract_t">Veitch AM, Radaelli F, Alikhan R, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut 2021; 70:1611.</a></li><li><a class="nounderline abstract_t">Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol 2022; 117:542.</a></li><li><a class="nounderline abstract_t">Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368:2113.</a></li><li><a class="nounderline abstract_t">Baron TH, Kamath PS, McBane RD. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clin Gastroenterol Hepatol 2014; 12:187.</a></li><li><a class="nounderline abstract_t">Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60:645.</a></li><li><a class="nounderline abstract_t">Lewis SR, Pritchard MW, Schofield-Robinson OJ, et al. Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev 2018; 7:CD012584.</a></li><li><a class="nounderline abstract_t">Tafur A, Douketis J. Perioperative management of anticoagulant and antiplatelet therapy. Heart 2018; 104:1461.</a></li><li><a class="nounderline abstract_t">Myles PS, Smith JA, Forbes A, et al. Stopping vs. Continuing Aspirin before Coronary Artery Surgery. N Engl J Med 2016; 374:728.</a></li><li><a class="nounderline abstract_t">Myles PS, Smith JA, Kasza J, et al. Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. J Thorac Cardiovasc Surg 2019; 157:633.</a></li><li><a class="nounderline abstract_t">Columbo JA, Lambour AJ, Sundling RA, et al. A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery. Ann Surg 2018; 267:1.</a></li><li><a class="nounderline abstract_t">Zakko L, Rustagi T, Douglas M, Laine L. No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents. Clin Gastroenterol Hepatol 2017; 15:46.</a></li><li><a class="nounderline abstract_t">Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect? Transfusion 2012; 52:695.</a></li><li><a class="nounderline abstract_t">Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.</a></li><li><a class="nounderline abstract_t">Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299:532.</a></li><li><a class="nounderline abstract_t">Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118:1894.</a></li><li><a class="nounderline abstract_t">Cruden NL, Harding SA, Flapan AD, et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv 2010; 3:236.</a></li><li><a class="nounderline abstract_t">Hawn MT, Graham LA, Richman JR, et al. The incidence and timing of noncardiac surgery after cardiac stent implantation. J Am Coll Surg 2012; 214:658.</a></li><li><a class="nounderline abstract_t">Kałuza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35:1288.</a></li><li><a class="nounderline abstract_t">Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42:234.</a></li><li><a class="nounderline abstract_t">Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005; 95:755.</a></li><li><a class="nounderline abstract_t">Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49:122.</a></li><li><a class="nounderline abstract_t">Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043.</a></li><li><a class="nounderline abstract_t">Wijeysundera DN, Wijeysundera HC, Yun L, et al. Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study. Circulation 2012; 126:1355.</a></li><li><a class="nounderline abstract_t">Boustière C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2011; 43:445.</a></li><li><a class="nounderline abstract_t">Grossman EB, Maranino AN, Zamora DC, et al. Antiplatelet medications increase the risk of post-polypectomy bleeding. Gastrointest Endosc 2010; 71:AB138.</a></li><li><a class="nounderline abstract_t">Singh M, Mehta N, Murthy UK, et al. Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. Gastrointest Endosc 2010; 71:998.</a></li><li><a class="nounderline abstract_t">Feagins LA, Iqbal R, Harford WV, et al. Low rate of postpolypectomy bleeding among patients who continue thienopyridine therapy during colonoscopy. Clin Gastroenterol Hepatol 2013; 11:1325.</a></li><li><a class="nounderline abstract_t">Gandhi S, Narula N, Mosleh W, et al. Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy. Aliment Pharmacol Ther 2013; 37:947.</a></li><li><a class="nounderline abstract_t">Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25:579.</a></li><li><a class="nounderline abstract_t">Hamada T, Yasunaga H, Nakai Y, et al. Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents. Endoscopy 2015; 47:997.</a></li><li><a class="nounderline abstract_t">Lee MG, Kim J, Lee SH, et al. Effect of sustained use of platelet aggregation inhibitors on post-endoscopic sphincterotomy bleeding. Dig Endosc 2014; 26:737.</a></li><li><a class="nounderline abstract_t">Onal IK, Parlak E, Akdogan M, et al. Do aspirin and non-steroidal anti-inflammatory drugs increase the risk of post-sphincterotomy hemorrhage--a case-control study. Clin Res Hepatol Gastroenterol 2013; 37:171.</a></li><li><a class="nounderline abstract_t">Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99:1785.</a></li><li><a class="nounderline abstract_t">Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59:44.</a></li><li><a class="nounderline abstract_t">Takeuchi T, Ota K, Harada S, et al. The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. BMC Gastroenterol 2013; 13:136.</a></li><li><a class="nounderline abstract_t">Burgess NG, Metz AJ, Williams SJ, et al. Risk factors for intraprocedural and clinically significant delayed bleeding after wide-field endoscopic mucosal resection of large colonic lesions. Clin Gastroenterol Hepatol 2014; 12:651.</a></li><li><a class="nounderline abstract_t">Cho SJ, Choi IJ, Kim CG, et al. Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. Endoscopy 2012; 44:114.</a></li><li><a class="nounderline abstract_t">Bahin FF, Naidoo M, Williams SJ, et al. Prophylactic endoscopic coagulation to prevent bleeding after wide-field endoscopic mucosal resection of large sessile colon polyps. Clin Gastroenterol Hepatol 2015; 13:724.</a></li><li><a class="nounderline abstract_t">Metz AJ, Bourke MJ, Moss A, et al. Factors that predict bleeding following endoscopic mucosal resection of large colonic lesions. Endoscopy 2011; 43:506.</a></li><li><a class="nounderline abstract_t">Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104:305.</a></li><li><a class="nounderline abstract_t">Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62:1217.</a></li><li><a class="nounderline abstract_t">Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27:2667.</a></li><li><a class="nounderline abstract_t">Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382:1714.</a></li><li><a class="nounderline abstract_t">Ferreira-González I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012; 60:1333.</a></li><li><a class="nounderline abstract_t">Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 2014; 35:1949.</a></li><li><a class="nounderline abstract_t">Usman MH, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 2009; 103:1107.</a></li></ol></div><div id="topicVersionRevision">Topic 2632 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26621548" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The management of antithrombotic agents for patients undergoing GI endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490017" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30145286" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : American College of Surgeons' Guidelines for the Perioperative Management of Antithrombotic Medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34362780" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35297395" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23718166" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of antithrombotic therapy in patients undergoing invasive procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735447" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22809746" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30019463" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217632" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Perioperative management of anticoagulant and antiplatelet therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933848" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Stopping vs. Continuing Aspirin before Coronary Artery Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30401528" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28463896" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27464591" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21854398" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870416" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252883" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949136" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18836135" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442357" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341201" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The incidence and timing of noncardiac surgery after cardiac stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758971" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Catastrophic outcomes of noncardiac surgery soon after coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875757" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757604" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risks of noncardiac surgery after coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207733" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477528" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893606" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21547880" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antiplatelet medications increase the risk of post-polypectomy bleeding</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20226452" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403011" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Low rate of postpolypectomy bleeding among patients who continue thienopyridine therapy during colonoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530880" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305758" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26126160" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673356" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of sustained use of platelet aggregation inhibitors on post-endoscopic sphincterotomy bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677232" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Do aspirin and non-steroidal anti-inflammatory drugs increase the risk of post-sphincterotomy hemorrhage--a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15330919" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722546" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010587" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24090728" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk factors for intraprocedural and clinically significant delayed bleeding after wide-field endoscopic mucosal resection of large colonic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271021" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25151254" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prophylactic endoscopic coagulation to prevent bleeding after wide-field endoscopic mucosal resection of large sessile colon polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21618150" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Factors that predict bleeding following endoscopic mucosal resection of large colonic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150346" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087761" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053008" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24004642" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999716" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510638" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19361598" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
